Veradermics Inc stock rises despite market weakness
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 30 2024
0mins
Source: Coinmarketcap
Veradermics Inc's stock price increased by 12.19% as it crossed above its 5-day SMA, indicating strong investor interest.
Despite the overall market decline, with the Nasdaq-100 down 0.51% and the S&P 500 down 0.27%, Veradermics Inc's stock experienced a significant rally. This movement suggests a sector rotation where investors are shifting their focus to specific stocks like Veradermics, which may be perceived as having strong growth potential or positive developments.
This price action could indicate a growing confidence in Veradermics Inc's future prospects, potentially driven by unique product offerings or market positioning that distinguishes it from broader market trends.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MANE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MANE
Wall Street analysts forecast MANE stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 102.790
Low
Averages
High
Current: 102.790
Low
Averages
High
About MANE
Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The Company is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The Company is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The Company is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Achieve Life Sciences Appoints New Board Members Ahead of Cytisinicline Launch
- New Board Members: Achieve Life Sciences has appointed Jeffrey Farrow and Reid Waldman to its Board of Directors, with Farrow bringing over $9 billion in acquisition experience in the biopharmaceutical sector and Waldman as the founder of Veradermics, both poised to provide strategic guidance for the upcoming NDA resubmission.
- Significant Market Potential: Farrow highlighted the large and underserved market for smoking dependence, with Cytisinicline expected to fill this gap as the first new prescription smoking cessation medication in nearly two decades, addressing the needs of approximately 25 million adult smokers in the U.S.
- Clinical Data Support: Waldman emphasized the encouraging results of Cytisinicline in clinical trials, particularly for e-cigarette cessation, indicating that the drug could become a new tool for nicotine dependence treatment, addressing the urgent needs of young patients and driving innovation in the biopharmaceutical field.
- Strategic Development Direction: Achieve Life Sciences' NDA application has received FDA Breakthrough Therapy designation, and with the extensive experience of the new board members, the company is advancing towards a successful launch of Cytisinicline, which is expected to create substantial value for both patients and shareholders.
See More
Veradermics Announces Phase 2/3 Results for VDPHL01
- Clinical Trial Results: Veradermics announced positive topline results from the Phase 2/3 ‘302' study of VDPHL01, which will be presented at the World Congress for Hair Research on May 30, 2026, potentially marking the first FDA-approved oral medication for hair loss in nearly 30 years, significantly impacting 50 million men in the U.S.
- Innovative Drug Development: VDPHL01 is a novel extended-release oral minoxidil formulation designed to enhance treatment efficacy by utilizing a unique gel matrix for sustained release, avoiding high peak concentrations of traditional minoxidil, and potentially becoming the only non-hormonal treatment option for both male and female patients with hair loss.
- Significant Market Potential: The hair loss treatment market is projected to reach approximately $30 billion by 2028, and the introduction of VDPHL01 will address the urgent demand for new therapies among 80 million Americans, filling a nearly 30-year gap in FDA-approved medications, thus holding substantial commercial value.
- Patent Protection: VDPHL01 is protected by a broad library of patents, with the earliest expiring in 2043, ensuring competitive advantages and long-term revenue potential for Veradermics in the biopharmaceutical sector.
See More
Siren Acquires New Stake in Veradermics
- New Investment Position: On May 14, 2026, Siren disclosed a new position in Veradermics by acquiring 1,505,374 shares valued at approximately $75.94 million, indicating strong confidence in the company's future growth prospects.
- Surging Stock Price: Veradermics' stock has skyrocketed over 500% since its February IPO, closing at $107.14 on May 13, with a market capitalization of $4.43 billion, reflecting high market expectations for its products.
- R&D Potential: Veradermics focuses on innovative therapies for dermatologic and aesthetic conditions, developing an oral treatment for hair loss that is expected to become the first FDA-approved oral hair loss treatment in nearly 30 years, presenting significant market potential.
- Strong Funding: The company raised approximately $766.8 million this year through its IPO and follow-on financing, with existing capital expected to fund operations into 2030, further solidifying its competitive position in the biopharmaceutical market.
See More
Veradermics Presents New Therapy at SCALE Conference
- Clinical Data Presentation: Veradermics showcases two E-posters at the 2026 SCALE conference, comparing the efficacy of VDPHL01 against existing minoxidil formulations, highlighting its potential advantages in male patients.
- Innovative Study Design: The first study involves a blinded retrospective assessment by nine independent dermatologists, indicating that VDPHL01 shows superior efficacy at 2 and 4 months compared to 6 months of immediate-release minoxidil, suggesting rapid onset of action.
- AI Technology Utilization: The second study employs the AI platform Global HairMap™ to compare outcomes of VDPHL01 with immediate-release minoxidil at 4 months for androgenetic alopecia, further validating its superior efficacy and potentially enhancing market acceptance.
- Broad Market Prospects: The androgenetic alopecia market is projected to reach $30 billion by 2028, and if approved, VDPHL01 would be the only FDA-approved non-hormonal oral treatment, addressing the growing market demand.
See More
Veradermics Reports Q1 Net Loss of $27.2 Million Amid IPO Success
- Financial Performance: Veradermics reported a net loss of $27.2 million for Q1 2026, compared to a net loss of $12.4 million in Q1 2025, indicating challenges in profitability that could impact investor confidence.
- Cash Position: As of March 31, 2026, the company had $390.8 million in cash, cash equivalents, and marketable securities, reflecting net proceeds from its upsized IPO completed in February 2026, enhancing its financial flexibility.
- IPO Dynamics: Veradermics successfully priced a $384 million upsized public offering and a $30 million private placement at $100 per share, demonstrating strong market demand for its stock, which may provide funding support for future business expansion.
- R&D Progress: The company achieved positive topline results in its Phase 2/3 study of VDPHL01 for mild-to-moderate pattern hair loss, further strengthening the outlook for its late-stage pipeline and potentially laying the groundwork for future product launches.
See More
VDPHL01 Positioned to Be First FDA-Approved Oral Treatment for Hair Loss in Nearly 30 Years
- Positive Clinical Results: In April 2026, Veradermics announced positive topline data from Study ‘302', showing that VDPHL01 achieved early, consistent, and robust hair growth in males with mild-to-moderate hair loss, positioning it to potentially become the first FDA-approved oral treatment for hair loss in nearly 30 years, marking a significant breakthrough in the field.
- Successful Financing: Veradermics raised approximately $766.8 million through its upsized IPO and follow-on financing, with these funds expected to support operations into 2030, covering multiple upcoming Phase 3 trials and the potential launch of VDPHL01, thereby enhancing the company's financial stability.
- Increased R&D Spending: The company reported R&D expenses of $20.9 million for Q1 2026, up 83.5% from $11.4 million in Q1 2025, primarily due to increased clinical development and personnel costs associated with VDPHL01, reflecting a strong commitment to advancing its product pipeline.
- Improved Financial Position: As of March 31, 2026, Veradermics had cash and cash equivalents totaling $390.8 million, significantly up from $141.9 million at the end of 2025, indicating that the company's successful capital market activities have provided robust financial support for future growth.
See More
Achieve Life Sciences Appoints New Board Members Ahead of Cytisinicline Launch
- New Board Members: Achieve Life Sciences has appointed Jeffrey Farrow and Reid Waldman to its Board of Directors, with Farrow bringing over $9 billion in acquisition experience in the biopharmaceutical sector and Waldman as the founder of Veradermics, both poised to provide strategic guidance for the upcoming NDA resubmission.
- Significant Market Potential: Farrow highlighted the large and underserved market for smoking dependence, with Cytisinicline expected to fill this gap as the first new prescription smoking cessation medication in nearly two decades, addressing the needs of approximately 25 million adult smokers in the U.S.
- Clinical Data Support: Waldman emphasized the encouraging results of Cytisinicline in clinical trials, particularly for e-cigarette cessation, indicating that the drug could become a new tool for nicotine dependence treatment, addressing the urgent needs of young patients and driving innovation in the biopharmaceutical field.
- Strategic Development Direction: Achieve Life Sciences' NDA application has received FDA Breakthrough Therapy designation, and with the extensive experience of the new board members, the company is advancing towards a successful launch of Cytisinicline, which is expected to create substantial value for both patients and shareholders.
See More
Veradermics Announces Phase 2/3 Results for VDPHL01
- Clinical Trial Results: Veradermics announced positive topline results from the Phase 2/3 ‘302' study of VDPHL01, which will be presented at the World Congress for Hair Research on May 30, 2026, potentially marking the first FDA-approved oral medication for hair loss in nearly 30 years, significantly impacting 50 million men in the U.S.
- Innovative Drug Development: VDPHL01 is a novel extended-release oral minoxidil formulation designed to enhance treatment efficacy by utilizing a unique gel matrix for sustained release, avoiding high peak concentrations of traditional minoxidil, and potentially becoming the only non-hormonal treatment option for both male and female patients with hair loss.
- Significant Market Potential: The hair loss treatment market is projected to reach approximately $30 billion by 2028, and the introduction of VDPHL01 will address the urgent demand for new therapies among 80 million Americans, filling a nearly 30-year gap in FDA-approved medications, thus holding substantial commercial value.
- Patent Protection: VDPHL01 is protected by a broad library of patents, with the earliest expiring in 2043, ensuring competitive advantages and long-term revenue potential for Veradermics in the biopharmaceutical sector.
See More
Siren Acquires New Stake in Veradermics
- New Investment Position: On May 14, 2026, Siren disclosed a new position in Veradermics by acquiring 1,505,374 shares valued at approximately $75.94 million, indicating strong confidence in the company's future growth prospects.
- Surging Stock Price: Veradermics' stock has skyrocketed over 500% since its February IPO, closing at $107.14 on May 13, with a market capitalization of $4.43 billion, reflecting high market expectations for its products.
- R&D Potential: Veradermics focuses on innovative therapies for dermatologic and aesthetic conditions, developing an oral treatment for hair loss that is expected to become the first FDA-approved oral hair loss treatment in nearly 30 years, presenting significant market potential.
- Strong Funding: The company raised approximately $766.8 million this year through its IPO and follow-on financing, with existing capital expected to fund operations into 2030, further solidifying its competitive position in the biopharmaceutical market.
See More
Veradermics Presents New Therapy at SCALE Conference
- Clinical Data Presentation: Veradermics showcases two E-posters at the 2026 SCALE conference, comparing the efficacy of VDPHL01 against existing minoxidil formulations, highlighting its potential advantages in male patients.
- Innovative Study Design: The first study involves a blinded retrospective assessment by nine independent dermatologists, indicating that VDPHL01 shows superior efficacy at 2 and 4 months compared to 6 months of immediate-release minoxidil, suggesting rapid onset of action.
- AI Technology Utilization: The second study employs the AI platform Global HairMap™ to compare outcomes of VDPHL01 with immediate-release minoxidil at 4 months for androgenetic alopecia, further validating its superior efficacy and potentially enhancing market acceptance.
- Broad Market Prospects: The androgenetic alopecia market is projected to reach $30 billion by 2028, and if approved, VDPHL01 would be the only FDA-approved non-hormonal oral treatment, addressing the growing market demand.
See More
Veradermics Reports Q1 Net Loss of $27.2 Million Amid IPO Success
- Financial Performance: Veradermics reported a net loss of $27.2 million for Q1 2026, compared to a net loss of $12.4 million in Q1 2025, indicating challenges in profitability that could impact investor confidence.
- Cash Position: As of March 31, 2026, the company had $390.8 million in cash, cash equivalents, and marketable securities, reflecting net proceeds from its upsized IPO completed in February 2026, enhancing its financial flexibility.
- IPO Dynamics: Veradermics successfully priced a $384 million upsized public offering and a $30 million private placement at $100 per share, demonstrating strong market demand for its stock, which may provide funding support for future business expansion.
- R&D Progress: The company achieved positive topline results in its Phase 2/3 study of VDPHL01 for mild-to-moderate pattern hair loss, further strengthening the outlook for its late-stage pipeline and potentially laying the groundwork for future product launches.
See More
VDPHL01 Positioned to Be First FDA-Approved Oral Treatment for Hair Loss in Nearly 30 Years
- Positive Clinical Results: In April 2026, Veradermics announced positive topline data from Study ‘302', showing that VDPHL01 achieved early, consistent, and robust hair growth in males with mild-to-moderate hair loss, positioning it to potentially become the first FDA-approved oral treatment for hair loss in nearly 30 years, marking a significant breakthrough in the field.
- Successful Financing: Veradermics raised approximately $766.8 million through its upsized IPO and follow-on financing, with these funds expected to support operations into 2030, covering multiple upcoming Phase 3 trials and the potential launch of VDPHL01, thereby enhancing the company's financial stability.
- Increased R&D Spending: The company reported R&D expenses of $20.9 million for Q1 2026, up 83.5% from $11.4 million in Q1 2025, primarily due to increased clinical development and personnel costs associated with VDPHL01, reflecting a strong commitment to advancing its product pipeline.
- Improved Financial Position: As of March 31, 2026, Veradermics had cash and cash equivalents totaling $390.8 million, significantly up from $141.9 million at the end of 2025, indicating that the company's successful capital market activities have provided robust financial support for future growth.
See More
